Key statistics
On Friday, Compass Pathways PLC (5Y6:DEU) closed at 5.05, 35.03% above the 52 week low of 3.74 set on Oct 31, 2024.
52-week range
Open | 4.84 |
---|---|
High | 5.10 |
Low | 4.64 |
Bid | 5.05 |
Offer | 5.15 |
Previous close | 4.94 |
Average volume | 5.28k |
---|---|
Shares outstanding | 68.42m |
Free float | 45.30m |
P/E (TTM) | -- |
Market cap | 372.89m USD |
EPS (TTM) | -2.19 USD |
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
- Compass Pathways announces second quarter 2024 financial results and business highlights
- Compass Pathways appoints Lori Englebert as Chief Commercial Officer
- Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
- Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
- Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
- Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
- Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
- Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights
- Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved
- Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
More ▼